Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1056/NEJMoa1609214 http://scihub22266oqcxt.onion/10.1056/NEJMoa1609214 C5247797!5247797!27806233     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       N+Engl+J+Med 2016 ; 375 (18): 1749-55 Nephropedia Template TP {{tp|p=27806233|t=2016. Fulminant Myocarditis with Combination Immune Checkpoint Blockade |pdf=|usr=}}{{27806233}} gab.com Text Fulminant Myocarditis with Combination Immune Checkpoint Blockade JO: N Engl J Med http://www.kidney.de/pget.php?&tw=1&pmid=27806233 #FOAvip Immune checkpoint inhibitors significantly improve clinical outcomes in numerous malignancies, but high-grade immune-related adverse events can occur, particularly with combination immunotherapy. Herein, we report two melanoma patients who developed fatal myocarditis following treatment with ipilimumab and nivolumab. Both patients developed myositis with rhabdomyolysis, early progressive and refractory cardiac electrical instability, and myocarditis with robust T-cell and macrophage infiltrates. Selective clonal T-cell populations infiltrating the myocardium were identical to those present in tumor and skeletal muscle. Pharmacovigilance data revealed that myocarditis occurred in 0.27% of patients treated with ipilimumab/nivolumab, suggesting this is a rare, potentially fatal, T-cell-driven drug reaction. Twit Text FOAVip Fulminant Myocarditis with Combination Immune Checkpoint Blockade ????N Engl J Med http://www.kidney.de/pget.php?&tw=1&pmid=27806233 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27806233 #FOAvip English Wikipedia <ref>{{Cite pmid|27806233}}</ref> Fulminant Myocarditis with Combination Immune Checkpoint Blockade #MMPMID27806233 Johnson DB; Balko JM; Compton ML; Chalkias S; Gorham J; Xu Y; Hicks M; Puzanov I; Alexander MR; Bloomer TL; Becker J; Slosky DA; Phillips EJ; Pilkinton MA; Craig-Owens L; Kola N; Plautz G; Reshef DS; Deutsch JS; Deering RP; Olenchock BA; Lichtman AH; Roden DM; Seidman CE; Koralnik IJ; Seidman JG; Hoffman RD; Taube JM; Diaz LA; Anders RA; Sosman JA; Moslehi JJ N Engl J Med 2016[Nov]; 375 (18): 1749-55 PMID27806233show ga Immune checkpoint inhibitors significantly improve clinical outcomes in numerous malignancies, but high-grade immune-related adverse events can occur, particularly with combination immunotherapy. Herein, we report two melanoma patients who developed fatal myocarditis following treatment with ipilimumab and nivolumab. Both patients developed myositis with rhabdomyolysis, early progressive and refractory cardiac electrical instability, and myocarditis with robust T-cell and macrophage infiltrates. Selective clonal T-cell populations infiltrating the myocardium were identical to those present in tumor and skeletal muscle. Pharmacovigilance data revealed that myocarditis occurred in 0.27% of patients treated with ipilimumab/nivolumab, suggesting this is a rare, potentially fatal, T-cell-driven drug reaction. äFulminant Myocarditis with Combination Immune Checkpoint Blockade (epmc).pdf DeepDyve Pubget Overpricing